Stockscreener 앱 받기
3.44
6.52%
-0.24
전일 마감가:
$3.68
열려 있는:
$3.68
하루 거래량:
715.86K
Relative Volume:
1.20
시가총액:
$207.85M
수익:
$40.37M
순이익/손실:
$-119.72M
주가수익비율:
-1.6861
EPS:
-2.0402
순현금흐름:
$-135.06M
1주 성능:
-8.99%
1개월 성능:
+3.61%
6개월 성능:
-14.43%
1년 성능:
-3.10%
1일 변동 폭
$3.415
$3.68
1주일 범위
$3.415
$3.83
52주 변동 폭
$2.8838
$5.55
Voyager Therapeutics Inc Stock (VYGR) Company Profile
명칭
Voyager Therapeutics Inc
전화
857-259-5340
주소
75 HAYDEN AVENUE, LEXINGTON, MA
Compare VYGR vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VYGR
Voyager Therapeutics Inc
|
3.44 | 207.85M | 40.37M | -119.72M | -135.06M | -2.0402 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-02 | 개시 | Citigroup | Buy |
| 2024-11-29 | 재개 | Wedbush | Outperform |
| 2024-10-16 | 개시 | Leerink Partners | Outperform |
| 2024-03-26 | 개시 | Guggenheim | Buy |
| 2024-03-19 | 개시 | H.C. Wainwright | Buy |
| 2024-03-07 | 개시 | Citigroup | Buy |
| 2024-01-02 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-05-10 | 개시 | Truist | Buy |
| 2023-03-10 | 개시 | Oppenheimer | Outperform |
| 2021-10-07 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2021-02-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2021-02-03 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2021-02-03 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-12-24 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2020-12-23 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-11-10 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2020-11-10 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-03-19 | 개시 | The Benchmark Company | Buy |
| 2020-02-06 | 개시 | Oppenheimer | Outperform |
| 2018-11-15 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2018-09-10 | 재개 | BTIG Research | Buy |
| 2018-09-10 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2018-06-04 | 개시 | H.C. Wainwright | Buy |
| 2018-03-12 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2018-03-12 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2018-02-02 | 개시 | Morgan Stanley | Overweight |
| 2017-11-28 | 재개 | Piper Jaffray | Overweight |
| 2017-10-31 | 개시 | Robert W. Baird | Outperform |
| 2017-10-27 | 개시 | Canaccord Genuity | Buy |
| 2017-10-23 | 재확인 | Stifel | Buy |
| 2017-10-12 | 개시 | Raymond James | Outperform |
| 2017-08-17 | 개시 | Evercore ISI | Outperform |
| 2017-07-28 | 재개 | Stifel | Buy |
모두보기
Voyager Therapeutics Inc 주식(VYGR)의 최신 뉴스
Voyager Therapeutics outlines gene therapy pipeline. Clinical partnerships frame the next phase - ad-hoc-news.de
Voyager Therapeutics outlines its gene therapy pipeline. Investors focus on neurology targets - ad-hoc-news.de
H.C. Wainwright Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $25 - Moomoo
VYGRVoyager Therapeutics Inc Latest SEC Filings - Finviz
Voyager Therapeutics : VYGR - 24/7 Wall St.
Enterprise value to revenue forward of Voyager Therapeutics, Inc. – NASDAQ:VYGR - TradingView
Voyager Therapeutics (VYGR) is Amongst the Best Stocks Under $10, With More Than 50% Upside - Insider Monkey
Price to sales forward of Voyager Therapeutics, Inc. – NASDAQ:VYGR - TradingView
Price to sales forward of Voyager Therapeutics, Inc. – FWB:VT6 - TradingView
Enterprise value to revenue forward of Voyager Therapeutics, Inc. – FWB:VT6 - TradingView
Price to earnings forward of Voyager Therapeutics, Inc. – NASDAQ:VYGR - TradingView
Enterprise value to EBITDA forward of Voyager Therapeutics, Inc. – NASDAQ:VYGR - TradingView
Price to book forward of Voyager Therapeutics, Inc. – FWB:VT6 - TradingView
Voyager to present Alzheimer’s gene therapy data at AAIC - Investing.com UK
Voyager to present Alzheimer’s gene therapy data at AAIC By Investing.com - Investing.com Australia
Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s - GlobeNewswire
VYGR Forecast — Price Target — Prediction for 2027 - TradingView
Voyager Therapeutics, Inc. Actuals & Estimates (NASDAQ:VYGR) - TradingView
H.C. Wainwright Reaffirms Their Buy Rating on Voyager Therapeutics (VYGR) - The Globe and Mail
Voyager Therapeutics, Inc. Actuals & Estimates (MUN:VT6) - TradingView
VT6 Forecast — Price Target — Prediction for 2027 - TradingView
Voyager Therapeutics Inc (VYGR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Voyager Therapeutics Inc (VYGR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Voyager Therapeutics Inc (VYGR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Voyager Therapeutics Inc (VYGR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
TD Cowen Maintains Voyager Therapeutics(VYGR.US) With Buy Rating - Moomoo
Voyager Therapeutics, Inc. Stock 12‑Month Price Target Raised to $15.38, Implies 325% Upside - TradingView
Voyager Therapeutics Inc (VYGR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Voyager Therapeutics Inc (VYGR) Institutional Confidence - TradingKey
Voyager Therapeutics Inc (VYGR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Voyager Therapeutics Inc (VYGR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Voyager Therapeutics Inc (VYGR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference - markets.businessinsider.com
Voyager Therapeutics (VYGR) director awarded 30,000 stock options at $3.43 - Stock Titan
Voyager Therapeutics (VYGR) grants director 30,000 stock options at $3.43 - Stock Titan
Voyager Therapeutics director granted 30,000 options | VYGR Insider Trading - Stock Titan
Voyager director granted options for 30,000 shares | VYGR Insider Trading - Stock Titan
Voyager Therapeutics (VYGR) director receives 30,000 stock options grant - Stock Titan
Voyager Therapeutics (VYGR) director granted 30,000 stock options at $3.43 - Stock Titan
Voyager Therapeutics (VYGR) grants director Glenn Pierce 30,000 stock options - Stock Titan
Voyager Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Onyia Jude - Moomoo
Voyager Therapeutics Expands Authorized Shares After Stockholder Vote - TipRanks
Voyager Therapeutics (NASDAQ: VYGR) doubles authorized common stock after 2026 vote - Stock Titan
Here's Why We're A Bit Worried About Voyager Therapeutics' (NASDAQ:VYGR) Cash Burn Situation - Yahoo Finance
Guggenheim Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Voyager’s tau-targeted gene therapy VY-1706 gains IND approval - BioWorld News
Voyager gets FDA clearance for Alzheimer’s gene therapy trial By Investing.com - Investing.com India
Voyager Therapeutics (VYGR) Gains FDA Approval for Alzheimer's G - GuruFocus
Voyager Therapeutics Receives FDA Clearance to Begin Clinical Trial of VY1706 Gene Therapy for Alzheimer’s Disease - Minichart
Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease - markets.businessinsider.com
Voyager Therapeutics IND Cleared for Alzheimer’s Gene Therapy - TipRanks
Voyager Therapeutics Inc (VYGR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):